Skip to main content
SpringerLink
Log in

Management of Reactivation of Hepatitis B and Hepatitis C During Antineoplastic Therapy

  • Chapter
  • First Online:
Principles and Practice of Cancer Infectious Diseases

Part of the book series: Current Clinical Oncology ((CCO))

  • 1450 Accesses

Abstract

Hepatitis viruses can cause serious illness in patient with cancer and those who have undergone stem cell transplantation (SCT). Patients with hematological malignancies chronically infected with either Hepatitis B virus (HBV) or Hepatitis C virus (HCV) are at risk for viral reactivation following chemotherapy. HBV reactivation is a common and serious complication but preventable. HCV has a lower reactivation rate following chemotherapy than HBV, but its presentation can be severe and nonpreventable. In this chapter, we review the management of reactivation of viral hepatitis during antineoplastic therapy affecting patients with cancer or SCT.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 2001;67:45–50.

    Article  PubMed  CAS  Google Scholar 

  2. Kawatani T, Suou T, Tajima F, Ooi S, Kawasaki H. Hepatitis C virus infection in acute leukemia with liver dysfunction. Eur J Haematol. 1993;51:254–5.

    Article  PubMed  CAS  Google Scholar 

  3. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–8.

    PubMed  CAS  Google Scholar 

  4. Law JK, Ho JK, Hoskins PJ, Erb SR, Steinbrecher UP, Yoshida EM. Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma. 2005;46:1085–9.

    Article  PubMed  Google Scholar 

  5. Alexopoulos CG, Vaslamatzis M, Hatzidimitriou G. Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours. Br J Cancer. 1999;81:69–74.

    Article  PubMed  CAS  Google Scholar 

  6. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152–62.

    Article  PubMed  Google Scholar 

  7. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009;49:S156–65.

    Article  PubMed  CAS  Google Scholar 

  8. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol. 2006;4:1076–81.

    Article  PubMed  CAS  Google Scholar 

  9. Su WP, Wen CC, Hsiung CA, et al. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol. 2005;11:5283–8.

    PubMed  CAS  Google Scholar 

  10. Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.

    Article  PubMed  CAS  Google Scholar 

  11. Liang R, Lau GK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem. J Clin Oncol. 1999;17:394–8.

    PubMed  CAS  Google Scholar 

  12. Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol. 2007;136:699–712.

    Article  PubMed  CAS  Google Scholar 

  13. Lau GK, Leung YH, Fong DY, et al. High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation. Blood. 2002;99:2324–30.

    Article  PubMed  CAS  Google Scholar 

  14. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307.

    Article  PubMed  CAS  Google Scholar 

  15. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–11.

    Article  PubMed  CAS  Google Scholar 

  16. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol. 2004;41:427–35.

    Article  PubMed  CAS  Google Scholar 

  17. Aksoy S, Harputluoglu H, Kilickap S, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.

    Article  PubMed  CAS  Google Scholar 

  18. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.

    Article  PubMed  CAS  Google Scholar 

  19. Jang JW, Choi JY, Bae SH, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006;43:233–40.

    Article  PubMed  CAS  Google Scholar 

  20. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.

    Article  PubMed  Google Scholar 

  21. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut. 2005;54:1597–603.

    Article  PubMed  CAS  Google Scholar 

  22. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.

    Article  PubMed  CAS  Google Scholar 

  23. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.

    Article  PubMed  CAS  Google Scholar 

  24. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology. 2002;36:702–9.

    Article  PubMed  CAS  Google Scholar 

  25. Torres HA, Mahale P, Davila M, Mulanovich V, Granwehr B, Kontoyiannis DP, Raad II. Hepatitis C virus infection in cancer patients: the story of a forgotten population. In: Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America; 21–24 Oct 2010. Canada: Vancouver; 2010.

    Google Scholar 

  26. Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005;74:158–65.

    Article  PubMed  Google Scholar 

  27. Ozguroglu M, Bilici A, Turna H, Serdengecti S. Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin’s lymphoma. Med Oncol. 2004;21:67–72.

    Article  PubMed  CAS  Google Scholar 

  28. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E. Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987–1991. Cancer. 1996;78:2210–5.

    Article  PubMed  CAS  Google Scholar 

  29. Keeffe EB. Hepatitis B virus reactivation with chemotherapy: diagnosis and prevention with antiviral prophylaxis. Rev Gastroenterol Disord. 2004;4:46–8.

    PubMed  Google Scholar 

  30. Peffault de Latour R, Ribaud P, Robin M, et al. Allogeneic hematopoietic cell transplant in HCV-infected patients. J Hepatol. 2008;48:1008–17.

    Google Scholar 

  31. Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol. 2003;25:184–92.

    Article  PubMed  Google Scholar 

  32. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83:1224–30.

    Article  PubMed  CAS  Google Scholar 

  33. Mahale P, Davila M, Chemaly RF, Lewis RE, Hwang JP, Kontoyiannis DP, Torres HA. Acute exacerbation of chronic hepatitis C in cancer patients. In: Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America; 21–24 Oct 2010. Canada: Vancouver; 2010.

    Google Scholar 

  34. Anoop P, Wotherspoon A, Matutes E. Severe liver dysfunction from hepatitis C virus reactivation following alemtuzumab treatment for chronic lymphocytic leukaemia. Br J Haematol. 2010;148:484–6.

    Article  PubMed  Google Scholar 

  35. Vento S, Cainelli F, Mirandola F, et al. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. Lancet. 1996;347:92–3.

    Article  PubMed  CAS  Google Scholar 

  36. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008;22:117–26.

    Article  PubMed  CAS  Google Scholar 

  37. Kanamori H, Fukawa H, Maruta A, et al. Case report: fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. Am J Med Sci. 1992;303:109–11.

    Article  PubMed  CAS  Google Scholar 

  38. Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant. 1994;13:417–22.

    PubMed  CAS  Google Scholar 

  39. Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood. 1995;86:1614–8.

    PubMed  CAS  Google Scholar 

  40. Fan FS, Tzeng CH, Hsiao KI, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant. 1991;8:417–20.

    PubMed  CAS  Google Scholar 

  41. Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood. 1997;90:4628–33.

    PubMed  CAS  Google Scholar 

  42. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–100.

    Article  PubMed  CAS  Google Scholar 

  43. Pawlotsky JM. Use and interpretation of virological tests for hepatitis C. Hepatology. 2002;36:S65–73.

    Article  PubMed  Google Scholar 

  44. Melisko ME, Fox R, Venook A. Reactivation of hepatitis C virus after chemotherapy for colon cancer. Clin Oncol (R Coll Radiol). 2004;16:204–5.

    Article  CAS  Google Scholar 

  45. Magy N, Cribier B, Schmitt C, et al. Effects of corticosteroids on HCV infection. Int J Immunopharmacol. 1999;21:253–61.

    Article  PubMed  CAS  Google Scholar 

  46. Ennishi D, Terui Y, Yokoyama M, et al. Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy. Am J Hematol. 2008;83:59–62.

    Article  PubMed  CAS  Google Scholar 

  47. Hsieh CY, Huang HH, Lin CY, et al. Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. J Clin Oncol. 2008;26:2584–6.

    Article  PubMed  Google Scholar 

  48. Keating MR. Antiviral agents for non-human immunodeficiency virus infections. Mayo Clin Proc. 1999;74:1266–83.

    Article  PubMed  CAS  Google Scholar 

  49. Papaevangelou V, Varsami M, Papadakis V, et al. Hepatitis C treatment concomitant to chemotherapy as “salvage” therapy in children with hematologic malignancies. Pediatr Infect Dis J. 2010;29:277–80.

    Article  PubMed  Google Scholar 

  50. Ljungman P, Andersson J, Aschan J, et al. Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation. Clin Infect Dis. 1996;23:167–9.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe, Unit 1460, Houston, TX, 77030, USA

    Harrys A. Torres

Authors
  1. Marta Davila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Harrys A. Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harrys A. Torres .

Editor information

Editors and Affiliations

  1. MD Anderson Cancer Center, Infectious Diseases Department, The University of Texas, 800 5th Avenue, Apt. 12-G, New York, 10065, New York, USA

    Amar Safdar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Davila, M., Torres, H.A. (2011). Management of Reactivation of Hepatitis B and Hepatitis C During Antineoplastic Therapy. In: Safdar, A. (eds) Principles and Practice of Cancer Infectious Diseases. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-644-3_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-644-3_17

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-643-6

  • Online ISBN: 978-1-60761-644-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation